Over 600 service members died suddenly after being given the drug Remdesivir by doctors despite it not being approved by the FDA to fight COVID-19.
A military whistleblower leaked explosive documents from the Department of Defense Joint Trauma System, revealing that the deadly drugs were administered “liberally” to service members regardless of its official FDA approval.
The whistleblower, who chose to remain anonymous under the pseudonym Daniel LeMay, first gave the documents over to journalist J.M. Phelps.
While discussing the contents of the documents, LeMay explained that the “initial trial depicted data manipulation in favor of remdesivir.”
After analyzing the data, he determined that clinical trials failed to use a genuine placebo group suitable for comparing to the results of those who received Remdesivir.
“The primary issue is with patient data. If we can’t verify the placebo group … then we can’t determine the actual efficacy of remdesivir,” he noted.
Between March 2020 and March 2024, 941 military service members died, with 63.9% of them taking remdesivi, data shows.
The drug’s potential dangers were hidden from the DoD.
RELATED: Whistleblower Targeted After Exposing 973% SURGE in Heart Failure Among Navy Pilots
Remdesivir has been found to be elthal in human patients, according to studies.
According to a 2019 article published in the New England Journal of Medicine, the drug caused the highest mortality rate of four potential Ebola therapies given to patients in the Democratic Republic of Congo – over half of those who received the drug died.
Meanwhile, Dr. Anthony Fauci’s National Institute of Allergy and Infectious Diseases awarded a $6 million grant to researchers at the University of North Carolina to “accelerate the development of a promising new drug (remdesivir) in the fight against deadly coronaviruses.”
In February 2020, Gilead was given FDA approval for a series of Phase 3 clinical trials to determine the suitability of remdesivir for COVID-19.
The following month, the DoD announced it was entering a “cooperative research and development agreement,” allowing them access to the drug.
As Phelps noted, the FDA has the legal power “to authorize the emergency use of an otherwise unapproved medical product if the Department of Defense … determines that there is a military emergency involving an agent that may cause imminently life-threatening and specific risk to U.S. forces.”
Another study published in the journal The Lancet in May 2020 showed that remdesivir was ceased in China because 12% of patients experienced adverse events.
A further study in 2021 published in the JAMA Network Open Journal found the drug was “not associated with survival,” and the patients given the drug had longer hospital stays and more deaths compared to those who were not given it.
Tragically, the service members were not told about the risks of the drug, meaning they could not provide informed consent.
“The whistleblower highlights what we’ve been saying all along. This drug is dangerous and, in most cases, fatal. There’s been no transparency or oversight. This should enrage people and make them push for an immediate investigation by Congress,” New Jersey state chair of FormerFedsGroup, Charlene Delfico, told The Defender.
RELATED: Italian MEP Who Exposed Vaccines, Lockdowns Finds Husband Strangled to Death in Car
